Today Champions Oncology Inc (CSBR) Stock Rises

September 17, 2017 - By Clifton Ray

The stock of Champions Oncology Inc (NASDAQ:CSBR) is a huge mover today! The stock increased 5.90% or $0.19 on September 15, reaching $3.41. About 303,095 shares traded or 886.38% up from the average. Champions Oncology Inc (NASDAQ:CSBR) has declined 35.84% since September 17, 2016 and is downtrending. It has underperformed by 52.54% the S&P500.
The move comes after 9 months positive chart setup for the $37.46M company. It was reported on Sep, 17 by Barchart.com. We have $3.65 PT which if reached, will make NASDAQ:CSBR worth $2.62M more.

More notable recent Champions Oncology Inc (NASDAQ:CSBR) news were published by: Prnewswire.com which released: “Champion Oncology Announces Additions to Leadership Team to Support Continued …” on August 05, 2015, also Prnewswire.com with their article: “Champions Oncology, Inc. Announces Closing of Public Offering of Common Stock” published on June 15, 2016, Prnewswire.com published: “Champions Oncology, Inc. Announces Pricing of Public Offering of Common Stock” on June 09, 2016. More interesting news about Champions Oncology Inc (NASDAQ:CSBR) were released by: Prnewswire.com and their article: “Champions Oncology Announces Plan to Open New Lab Facility in Rockville, Maryland” published on March 16, 2017 as well as Marketwatch.com‘s news article titled: “Champions Oncology shares surge 8% on news of AstraZeneca collaboration” with publication date: August 21, 2017.

Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company has market cap of $37.46 million. The Firm has two business divisions: Personalized Oncology Solutions and Translational Oncology Solutions (TOS). It currently has negative earnings. The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.